The UK and US have announced a important commercial pact that will preserve no levies on UK pharmaceutical products being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This move guarantees that import taxes on these key products will stay at zero for a duration of 36 months.
This deal comes after previous threats to dramatically increase duties on branded pharmaceutical products, with increases discussed up to double the cost.
"This arrangement between the UK strengthens the worldwide climate for cutting-edge drugs and brings long-overdue balance to American-British medicine commerce," a statement said.
Trade Importance
Drugs represent one of the UK's biggest export categories to the America, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year prior to last September, the UK exported drugs worth billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This deal protects employment, stimulates funding and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Detailed UK Commitments
The agreement involves several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to raise total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
This agreement follows a long-running dispute between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were exacerbated by arguments that American patients were charged significantly more for the same drugs than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward US facilities.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its total funding over the previous ten-year period.
